Patricia Eckert compensation by year
ENZO BIOCHEM Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $204,500 | $264,231 |
| Bonus | $185,000 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $53,500 | $100,750 |
| Non-equity incentive | $50,000 | $112,500 |
| Pension and deferred compensation | $0 | $0 |
| All other | $10,559 | $12,559 |
| Total | $503,559 | $490,040 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ENZO BIOCHEM INC DEF 14A filed November 27, 2024, accession 0001213900-24-103467, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ENZO BIOCHEM INC filed document, accession 0001213900-24-103467. Every figure is read from that document and cited to the page and table it appears in. Filed November 27, 2024.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 16,667 | — | $2.21 |
| Option | 16,667 | — | $2.33 |
| Option | 16,667 | — | $2.29 |
| Option | 100,000 | — | $2.00 |
| Option | 75,000 | — | $1.38 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ENZO BIOCHEM INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2024 proxy (filed November 27, 2024)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-08-20 | Disposition to the issuer derivative | — | 50,000 | — | 0 |
| 2025-08-20 | Disposition to the issuer | — | 28,328 | — | 0 |
| 2025-08-20 | Disposition to the issuer derivative | — | 100,000 | — | 0 |
| 2025-08-20 | Disposition to the issuer derivative | — | 75,000 | — | 0 |
| 2025-08-20 | Disposition to the issuer derivative | — | 25,000 | — | 0 |
| 2025-08-20 | Disposition to the issuer derivative | — | 25,000 | — | 0 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ENZO BIOCHEM’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kara Cannon | Chief Executive Officer | $999,352 |
| Hamid Erfanian | Former Chief Executive Officer | $820,400 |
| Patricia Eckert · this page | Chief Financial Officer | $490,040 |
The full ENZO BIOCHEM compensation record
free company briefThis page is one person within ENZO BIOCHEM's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ENZO BIOCHEM's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ENZO BIOCHEM's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ENZ
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.